Sutro Biopharma (STRO)
(Delayed Data from NSDQ)
$3.42 USD
-0.05 (-1.44%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $3.43 +0.01 (0.29%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Sutro Biopharma, Inc. (STRO) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$12.89 | $20.00 | $8.00 | 271.47% |
Price Target
Based on short-term price targets offered by nine analysts, the average price target for Sutro Biopharma, Inc. comes to $12.89. The forecasts range from a low of $8.00 to a high of $20.00. The average price target represents an increase of 271.47% from the last closing price of $3.47.
Analyst Price Targets (9 )
Broker Rating
Sutro Biopharma, Inc. currently has an average brokerage recommendation (ABR) of 1.20 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 10 brokerage firms. The current ABR compares to an ABR of 1.20 a month ago based on 10 recommendations.
Of the 10 recommendations deriving the current ABR, nine are Strong Buy, representing 90% of all recommendations. A month ago, Strong Buy represented 90%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 9 | 9 | 9 | 9 | 9 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.20 | 1.20 | 1.20 | 1.20 | 1.20 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/3/2024 | Truist Securities | Asthika S Goonewardene | Strong Buy | Strong Buy |
4/3/2024 | Piper Sandler | Edward A Tenthoff | Strong Buy | Strong Buy |
3/26/2024 | Wedbush Securities | David M Nierengarten | Strong Buy | Strong Buy |
3/5/2024 | JMP Securities | Reni Benjamin | Strong Buy | Strong Buy |
3/1/2024 | H.C. Wainwright & Co. | Andrew S Fein | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.20 |
ABR (Last week) | 1.20 |
# of Recs in ABR | 10 |
Average Target Price | $12.89 |
LT Growth Rate | 1.70% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 69 of 252 |
Current Quarter EPS Est: | -0.88 |